These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 15326376)

  • 1. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53.
    Carrassa L; Broggini M; Erba E; Damia G
    Cell Cycle; 2004 Sep; 3(9):1177-81. PubMed ID: 15326376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
    Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
    Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated cyclin G2 expression intersects with DNA damage checkpoint signaling and is required for a potent G2/M checkpoint arrest response to doxorubicin.
    Zimmermann M; Arachchige-Don AS; Donaldson MS; Dallapiazza RF; Cowan CE; Horne MC
    J Biol Chem; 2012 Jun; 287(27):22838-53. PubMed ID: 22589537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug discovery targeting Chk1 and Chk2 kinases.
    Zhou BB; Sausville EA
    Prog Cell Cycle Res; 2003; 5():413-21. PubMed ID: 14593735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.
    Pan Y; Ren KH; He HW; Shao RG
    Cancer Biol Ther; 2009 Aug; 8(16):1559-66. PubMed ID: 19502782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
    Xiao Z; Xue J; Sowin TJ; Zhang H
    Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
    Pabla N; Huang S; Mi QS; Daniel R; Dong Z
    J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase.
    Jin J; Ang XL; Ye X; Livingstone M; Harper JW
    J Biol Chem; 2008 Jul; 283(28):19322-8. PubMed ID: 18480045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
    Demidova AR; Aau MY; Zhuang L; Yu Q
    J Biol Chem; 2009 Feb; 284(7):4132-9. PubMed ID: 19060337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
    Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
    Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.
    Gaul L; Mandl-Weber S; Baumann P; Emmerich B; Schmidmaier R
    J Cancer Res Clin Oncol; 2008 Feb; 134(2):245-53. PubMed ID: 17653574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog.
    He G; Kuang J; Khokhar AR; Siddik ZH
    Gynecol Oncol; 2011 Aug; 122(2):402-9. PubMed ID: 21592546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stalled replication induces p53 accumulation through distinct mechanisms from DNA damage checkpoint pathways.
    Ho CC; Siu WY; Lau A; Chan WM; Arooz T; Poon RY
    Cancer Res; 2006 Feb; 66(4):2233-41. PubMed ID: 16489026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
    Levesque AA; Fanous AA; Poh A; Eastman A
    Mol Cancer Ther; 2008 Feb; 7(2):252-62. PubMed ID: 18281511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2.
    Carlessi L; Buscemi G; Larson G; Hong Z; Wu JZ; Delia D
    Mol Cancer Ther; 2007 Mar; 6(3):935-44. PubMed ID: 17363488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.
    Reinhardt HC; Aslanian AS; Lees JA; Yaffe MB
    Cancer Cell; 2007 Feb; 11(2):175-89. PubMed ID: 17292828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.
    Turner J; Koumenis C; Kute TE; Planalp RP; Brechbiel MW; Beardsley D; Cody B; Brown KD; Torti FM; Torti SV
    Blood; 2005 Nov; 106(9):3191-9. PubMed ID: 16014567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents.
    Damia G; Broggini M
    Cell Cycle; 2004 Jan; 3(1):46-50. PubMed ID: 14657665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naphthalimides induce G(2) arrest through the ATM-activated Chk2-executed pathway in HCT116 cells.
    Zhu H; Miao ZH; Huang M; Feng JM; Zhang ZX; Lu JJ; Cai YJ; Tong LJ; Xu YF; Qian XH; Ding J
    Neoplasia; 2009 Nov; 11(11):1226-34. PubMed ID: 19881958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.